Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study
- 1 August 2020
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (8) , 1126-1128
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK PathwaysFrontiers in Immunology, 2018
- Calcium crystal deposition diseases — beyond goutNature Reviews Rheumatology, 2018
- Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases reportJoint Bone Spine, 2018
- Therapy for CPPD: Options and EvidenceCurrent Rheumatology Reports, 2018
- Pathophysiology of articular chondrocalcinosis—role of ANKHNature Reviews Rheumatology, 2010
- Inflammatory microcrystals stimulate interleukin‐6 production and secretion by human monocytes and synoviocytesArthritis & Rheumatism, 1989